Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$2.11MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mathai Mammen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Beta
- 5.03
- Country
- US
Financials
PBLS has only 5 quarterly periods on file — the charts below show the full history available.
Revenue
$2.11M+1328.4%Net Income
$-44.49MEBITDA
$-54.74MFree Cash Flow
$-41.69MEPS (diluted)
$-0.36Shares Outstanding (diluted)
123.59M+4.6%Operating Expenses
$56.85MCash & Debt
$871.62MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-145.89M | $-1.58 |
| 2024 | $0.00 | $-117.91M | $-1.37 |
Valuation
PBLShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
20-84.62%Social Signal Score
Mentions (13)
- Newsglobenewswire.com·10d ago·Negative
…h, cash equivalents and marketable securities, expected to fund operations into 2030 CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today reported financial results and business updates for the third quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·19d ago·Negative
Parabilis Medicines to Participate in Upcoming November Investor Conferences CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced that Mathai Mammen, M.D.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Parabilis Medicines: Bullish On Zolucatetide's Broad Oncology Potential Zolucatetide gives PBLS potential in desmoid tumors, but it also has other Wnt-driven indications that could grow its TAM over time. PBLS's PEDESTAL trial is now a clearer R&D path, as long as early responses are corroborated in that Phase 3 study for tumor control. Management's runway projection also suggests they have flexibility and should be able to reach pivotal milestones with Zolucatetide.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
View source ↗ - Newsmarketbeat.com·29d ago·Neutral
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027 Parabilis Medicines NASDAQ: PBLS presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid, reporting tumor responses, disease control and an FDA-aligned plan for a registrational phase III study.
View source ↗ - Newsglobenewswire.com·29d ago·Neutral
…ficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced updated safety and efficacy data for zolucatetide, the first and only direct inhibitor of the β-catenin:TCF interaction, in patients with de…
View source ↗ - Newsseekingalpha.com·33d ago·Positive
…ne. Lead asset zolucatetide (zolu) shows robust early efficacy in desmoid tumors and craniopharyngioma, with favorable safety and FDA Orphan/Fast Track designations. PBLS benefits from a $125M upfront/Regeneron partnership, $1.1B cash, and a projected cash runway into 2030, minimizing near-term dilution risk.
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors
View source ↗ - News (RSS)seekingalpha·67d ago·Positive
Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)investing·89d ago·Neutral
Parabilis Medicines adds former J&J oncology executive to board
View source ↗ - Newsglobenewswire.com·89d ago·Negative
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D. CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L.
View source ↗ - Newsseekingalpha.com·100d ago·Negative
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway into 2030 to support clinical trials, platform expansion, and reduce financing risk. Early zolucatetide data in desmoid tumors show 100% tumor reduction and 74% objective response, with a favorable safety profile versus com…
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $-0.45 per share
Typical surprise -653.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.36 vs $-0.36beat
- Thu, Aug 13$-2.32 vs $-0.17miss
Estimates and results for PBLS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PBLS officers and directors.
- Bought
- $441.4m
- Sold
- —
14 trades
0 trades
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Sebulsky Alanbought
- Sebulsky Alanbought
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PBLS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
